Dr. Wenming Cao 曹文明
Chief Physician
Department of Medical Oncology (Breast Cancer), Zhejiang Cancer Hospital, Hangzhou
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Medical treatment of breast cancer, including chemotherapy, endocrine therapy, targeted therapy, and immunotherapy. Genetic testing and counseling for hereditary breast cancer.
Dr. Cao holds a PhD from Zhejiang University (2013) and has worked at Zhejiang Cancer Hospital since 2005. Dr. Cao completed visiting studies at MD Anderson Cancer Center (2014–2015). Research focuses on precision medicine based on molecular detection and mechanisms of hereditary breast cancer. Dr. Cao established one of the first breast tumor genetics clinics in the province and participates in new drug clinical trials.
Professional roles
- Standing Committee Member, Family Hereditary Tumor Professional Committee, China Anti-Cancer Association
- Young Expert, Breast Cancer Professional Committee, China Anti-Cancer Association
- Vice Chair, Family Hereditary Tumor Professional Committee, Zhejiang Anti-Cancer Association
- Standing Committee Member, Tumor Metastasis Professional Committee, Zhejiang Anti-Cancer Association
Name order: in Chinese the family name comes first (Cao Wenming). Papers usually list the name as Wenming Cao or Cao W.
Selected publications
53 papers on PubMed matched by name and affiliation; 18 as first or senior author since 2016. Most recent first- or senior-author papers:
- Ther Adv Med Oncol, 2026 (senior author): Homologous recombination deficiency correlates with tumor-infiltrating lymphocytes and predicts patient outcomes in hormone receptor-positive/HER2-negative breast cancer. PubMed 42369725
- J Pathol Clin Res, 2024 (senior author): High chromosomal instability is associated with higher 10-year risks of recurrence for hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer patients: clinical evidence from a large-scale, multiple-site, retrospective study. PubMed 39545625
- Eur J Med Res, 2024 (senior author): AcornHRD: an HRD algorithm highly associated with anthracycline-based neoadjuvant chemotherapy in breast cancer in China. PubMed 39014466
- Ther Adv Med Oncol, 2024 (senior author): HR-positive/HER2-negative breast cancer arising in patients with or without BRCA2 mutation: different biological phenotype and similar prognosis. PubMed 38606163
- Discov Med, 2024 (senior author): Characterizing the Efficacy and Safety of Chemotherapy Plus Everolimus in HER2-Negative Metastatic Breast Cancer Harboring Altered PI3K/AKT/mTOR. PubMed 38531793
- J Cancer Res Clin Oncol, 2023 (senior author): A comprehensive analysis of Fanconi anemia genes in Chinese patients with high-risk hereditary breast cancer. PubMed 37566130
- NPJ Breast Cancer, 2023 (senior author): Resistance to anti-HER2 therapy associated with the TSC2 nonsynonymous variant c.4349 C > G (p.Pro1450Arg) is reversed by CDK4/6 inhibitor in HER2-positive breast cancer. PubMed 37160904
- Front Oncol, 2023 (senior author): The progress in our understanding of CIN in breast cancer research. PubMed 36874134
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion